恆星科技(002132.SZ):回購賬户所持2544.57萬股已過户至第二期員工持股計劃賬户
格隆匯6月7日丨恆星科技(002132.SZ)公佈,公司於2021年6月4日收到中國證券登記結算有限責任公司深圳分公司出具的《證券過户登記確認書》,公司開立的回購專用證券賬户所持有的2544.57萬股(佔公司總股本的2.03%)股票已通過非交易過户形式過户至“河南恆星科技股份有限公司—第二期員工持股計劃”證券專用賬户。
公司回購專用證券賬户中剩餘回購股份將依據相關規定將其作為未來員工持股計劃或股權激勵計劃的股票來源。此次員工持股計劃的非交易過户情況與股東大會審議通過的方案不存在差異。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.